The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Fidelis SeniorCare Inc. (Michigan Heath Plan)
Advised Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space
Global Television
Advised Catalyst Investment Managers on the sale of its portfolio company Global Television, Australia’s largest provider of outsourced broadcasting and video production services, to NEP Inc., a leading provider of total broadcast solutions in the US, UK and Brazil. NEP is majority-owned by private funds managed by Crestview Partners
Open Colleges Australia Pty Ltd
Advised Open Colleges, Australia’s leading privately owned online provider in the high-growth vocational education and training sector, on the sale of a 70% stake (plus exit arrangements for the balance) to Apollo Education Group, Inc., one of North America’s largest private education providers
AT&T (Connecticut Wireline Operations)
Advised AT&T Inc. on the sale of its wireline operations in the State of Connecticut to Frontier Communications
Aztec (subsidiary of Dentsu Inc.)
Advised Dentsu Inc., Asia’s largest advertising agency, on the sale of its retail data analytics subsidiary Aztec, to IRI, a global market research company
Lincoln Benefit Life, a subsidiary of the Allstate Corporation
Advised the limited partners of Resolution Life L.P. in the proposed acquisition by its subsidiary, Resolution Life Holdings, Inc., of Lincoln Benefit Life for $600mm
Warner Chilcott, plc
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
Healthcare Finance Group, LLC
Advised Fifth Street Finance Corp., a specialty finance company with approximately $2 billion of assets under management, on the acquisition of Healthcare Finance Group, LLC, a specialty lender providing asset-based lending and term loan products to the healthcare industry
SUPERVALU, Inc.
Advised SUPERVALU, a leading food retailer, on the sale of its New Albertsons, Inc. subsidiary to an investor group led by Cerberus Capital Management L.P. In addition to the sale, Greenhill also advised the Company on a simultaneous equity tender offer by Cerberus for up to a 30% stake in pro forma SUPERVALU
TNS, Inc.
Advised the Special Committee of the Board of Directors of TNS, Inc., a leading global provider of data communications and interoperability solutions, on its sale to Siris Capital Group, a private equity firm focused on complex, control equity investments in the telecom, technology and technology-enabled business service sectors
Investments of AP Alternative Assets, L.P.
Advised the Special Committee of the Conflicts Committee of the Board of Directors of Athene Holding Ltd. in connection with the purchase of non-cash investment assets of AP Alternative Assets L.P.
Target Corporation’s REDcard credit card assets
Advised The Toronto-Dominion Bank Group on its acquisition of Target Corporation’s REDcard credit card assets
Phaidon Press Limited
Advised Phaidon Press Limited (“Phaidon”) and its owner, Richard Schlagman, on the sale of the company to the family of Leon Black. Founded in 1923, Phaidon is a leading branded publishing and media company focused on the visual arts, culture and lifestyle sectors
The Hartford’s Individual Life Insurance Business
Advised The Hartford, a leading provider of insurance and wealth management services, on the divestiture of its Individual Life Insurance Business to Prudential Financial, Inc.
The Hartford’s Retirement Plans Group
Advised The Hartford, a leading provider of insurance and wealth management services, on the divestiture of its Retirement Plans Group to Massachusetts Mutual Life Insurance Company, a leading mutual life insurance company
Performance Coatings division of E. I. DuPont de Nemours and Company
Advised E. I. Du Pont de Nemours and Company, a global diversified chemicals company, on the sale of its Performance Coatings division to an affiliate of The Carlyle Group, a leading private equity firm
Coventry Health Care Inc.
Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna
Robbins-Gioia Inc.
Advised Informa plc on the sale of its subsidiary, Robbins-Gioia Inc., to a group of private investors
Merlin Securities LLC
Advised Merlin Securities LLC, a leading prime brokerage company in the US, on its sale to Wells Fargo
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
iNova Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
American Dental Partners, Inc.
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
The Synovate Group
Advised Aegis Group plc on the sale of The Synovate Group, a leading global provider of custom market research, to Ipsos S.A.
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion